Eads & Heald Wealth Management Lowers Stock Holdings in Edwards Lifesciences Corporation $EW

Eads & Heald Wealth Management lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,383 shares of the medical research company’s stock after selling 747 shares during the quarter. Eads & Heald Wealth Management’s holdings in Edwards Lifesciences were worth $1,281,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $26,000. SouthState Corp purchased a new position in Edwards Lifesciences in the first quarter worth $27,000. Global X Japan Co. Ltd. grew its position in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after acquiring an additional 216 shares in the last quarter. Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 205 shares during the last quarter. Finally, Rossby Financial LCC purchased a new stake in Edwards Lifesciences during the first quarter valued at about $29,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EW. Evercore ISI increased their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the company an “in-line” rating in a research report on Friday, July 25th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Monday, September 22nd. Truist Financial lifted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Finally, Royal Bank Of Canada increased their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.61.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $77.03 on Monday. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The stock has a market cap of $45.22 billion, a P/E ratio of 11.08, a price-to-earnings-growth ratio of 3.71 and a beta of 1.05. The firm’s fifty day simple moving average is $78.50 and its 200 day simple moving average is $76.01. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.